Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupAcute LeukemiasMyeloproliferative neoplasms (MPN) and myelodysplastic neoplasms (MDS)TransplantationDiseaseAcute Myeloid LeukemiaMyelodysplastic NeoplasmsStem Cell Transplantation, AllogeneicSubgroupFLT3 mutationHigh riskICD10C92.0-C92.5-C92.6-C92.7-C92.8-C92.9-C93.0-D46.-MeSHLeukemia, Myeloid, AcuteMyelodysplastic SyndromesSequenceDAUN60/CYTA200/MDST50, AML Ind. (PID1079) -|- Cons. (PID1080) -|- maint. (PID1081)ChemotherapyChemo-substanceAzacitidineCytarabineGlasdegibLenalidomideMelphalanMidostaurinChemo-substanceAzacitidineCytarabineGlasdegibLenalidomideMelphalanMidostaurinChemo-substanceAzacitidineCytarabineGlasdegibLenalidomideMelphalanMidostaurinChemo-substanceAzacitidineCytarabineGlasdegibLenalidomideMelphalanMidostaurinNo. Substances12 RadiotherapySupportive therapySupportive substanceCiprofloxacinDexamethasoneGranisetronPosaconazoleSupportive substanceCiprofloxacinDexamethasoneGranisetronPosaconazoleSupportive substanceCiprofloxacinDexamethasoneGranisetronPosaconazoleSupportive substanceCiprofloxacinDexamethasoneGranisetronPosaconazoleNo. Substances123Protocol classificationTherapy classificationalternativecurrent standardIntensityLow doseStandard doseTherapy indicationFirst lineRelapse therapyseveral possibleTherapy phaseMaintenanceTherapy intentioncurativecurative or palliativepalliativeRisksAnemia Hb below 8g/dlAstheniaColitisDiarrheaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Febrile NeutropeniaHyperbilirubinemiaHyperglycemiaHypokalemiaHyponatremiaHypophosphatemiaIncrease AminotransferasesInfectionsNeutropeniaPainPneumoniaRenal FailureSepsisThrombocytopenia below 50 000/µl only studiesPublicationAuthorCortes JECraddock CLübbert MPlatzbecker USchroeder TStone RStratmann JDiseaseAML- oder CMML-Rezidiv nach allogener StammzelltranplantationAML- oder MDS-Rezidiv nach allogener StammzelltranplantationAML oder Hochrisiko MDS, nicht für eine Standard-Induktionschemotherapie geeignet, ECOG 0-2de-novo oder sekundäre AML, mindestens 1 nicht-kurative Vortherapie, über 65 JahreDrohendes AML- oder MDS-Rezidiv nach allogener Stammzelltranplantation (Spenderchimärismus <80%)neudiagnostizierte AML, Erhaltung bei Patienten in kompletter Remission, FLT3-Mutation, ErstlinieOriginCarl Gustav Carus Technical University of Dresden, Dresden, Germany, RELAZA trialDana-Farber Cancer Institute, Boston MADivision Hematology and Oncology, University of Freiburg Medical Center, Freiburg, GermanyHematology and Oncology, Goethe University, Frankfurt, Frankfurt am Main, GermanyOncology and Clinical Immunology, University of Duesseldorf, Medical Faculty, Duesseldorf, GermanyUniversity of Birmingham, Birmingham, United KingdomUniversity of Texas, MD Anderson Cancer Center, Houston, USAProtocols in Revision 7 protocols foundProtocols under revision.Azacitidine 100, Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplantation (PID2302 V1.0)Azacitidine 100, Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplantation, Variant 1. (PID2320 V1.0)Azacitidine 75 / Lenalidomide 25, Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplantation (PID827 V1.2)Azacitidine 75, Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplantation. (PID2327 V1.0)Cytarabine 20 / Glasdegib 100, Acute Myeloid Leukemia and Myelodysplastic Syndrome (PID1674 V1.0)Melphalan 2, Acute Myeloid Leukemia, over 65 years of age (PID1735 V1.1)Midostaurin 50, Acute Myeloid Leukemia, maintenance (PID1081 V1.1)
